|
EP0281604B1
(en)
|
1986-09-02 |
1993-03-31 |
Enzon Labs Inc. |
Single polypeptide chain binding molecules
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
ES2156149T3
(es)
|
1992-12-04 |
2001-06-16 |
Medical Res Council |
Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
|
|
AUPO591797A0
(en)
|
1997-03-27 |
1997-04-24 |
Commonwealth Scientific And Industrial Research Organisation |
High avidity polyvalent and polyspecific reagents
|
|
US7083784B2
(en)
|
2000-12-12 |
2006-08-01 |
Medimmune, Inc. |
Molecules with extended half-lives, compositions and uses thereof
|
|
US7595378B2
(en)
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
|
FR2858235B1
(fr)
|
2003-07-31 |
2006-02-17 |
Lab Francais Du Fractionnement |
Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
|
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
|
US7767792B2
(en)
|
2004-02-20 |
2010-08-03 |
Ludwig Institute For Cancer Research Ltd. |
Antibodies to EGF receptor epitope peptides
|
|
ES2425749T3
(es)
|
2004-03-31 |
2013-10-17 |
The General Hospital Corporation |
Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico
|
|
EP3042964A1
(en)
|
2004-06-04 |
2016-07-13 |
Genentech, Inc. |
Egfr mutations
|
|
WO2006028936A2
(en)
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
|
CN102580084B
(zh)
|
2005-01-21 |
2016-11-23 |
健泰科生物技术公司 |
Her抗体的固定剂量给药
|
|
EP2505591A1
(en)
|
2005-02-11 |
2012-10-03 |
Memorial Sloan-Kettering Cancer Center |
Methods and compositions for detecting a drug resistant EGFR mutant
|
|
MX2007009963A
(es)
|
2005-02-24 |
2007-09-26 |
Amgen Inc |
Mutaciones del receptor del factor de crecimiento epidermico.
|
|
NZ561211A
(en)
|
2005-03-25 |
2011-03-31 |
Genentech Inc |
Methods and compositions for modulating hyperstabilized C-met
|
|
AU2006232287B2
(en)
|
2005-03-31 |
2011-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
|
PT1999154E
(pt)
|
2006-03-24 |
2013-01-24 |
Merck Patent Gmbh |
Domínios proteicos heterodiméricos modificados
|
|
JP2009541275A
(ja)
|
2006-06-22 |
2009-11-26 |
ノボ・ノルデイスク・エー／エス |
二重特異性抗体の生産
|
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
|
AU2008239594B2
(en)
|
2007-04-13 |
2013-10-24 |
Beth Israel Deaconess Medical Center |
Methods for treating cancer resistant to ErbB therapeutics
|
|
KR20100058509A
(ko)
|
2007-07-31 |
2010-06-03 |
메디뮨 엘엘씨 |
다중특이적 에피토프 결합 단백질 및 이의 용도
|
|
US7892770B2
(en)
|
2007-08-24 |
2011-02-22 |
Van Andel Research Institute |
Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
|
|
AU2008343589A1
(en)
|
2007-12-19 |
2009-07-09 |
Centocor Ortho Biotech Inc. |
Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
WO2010129304A2
(en)
|
2009-04-27 |
2010-11-11 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
HRP20241208T1
(hr)
|
2010-04-20 |
2024-11-22 |
Genmab A/S |
Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
|
|
US8962808B2
(en)
|
2010-05-05 |
2015-02-24 |
The Research Foundation For The State University Of New York |
EGFR-related polypeptides and methods of use
|
|
ES2758994T3
(es)
|
2010-11-05 |
2020-05-07 |
Zymeworks Inc |
Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
|
|
ES2860748T3
(es)
|
2011-01-24 |
2021-10-05 |
Gilead Sciences Inc |
Anticuerpos selectivos para células que presentan EGFR con alta densidad
|
|
BR112013023918A2
(pt)
|
2011-03-25 |
2016-12-13 |
Glenmark Pharmaceuticals Sa |
imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural
|
|
KR20130036993A
(ko)
|
2011-10-05 |
2013-04-15 |
삼성전자주식회사 |
ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
|
|
RU2654567C2
(ru)
|
2011-10-11 |
2018-05-21 |
Дженентек, Инк. |
Улучшенная сборка биспецифических антител
|
|
BR112014010580B1
(pt)
|
2011-11-04 |
2021-01-12 |
Zymeworks, Inc. |
constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
|
|
MX361088B
(es)
*
|
2012-11-21 |
2018-11-26 |
Janssen Biotech Inc |
Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos.
|
|
US20170275367A1
(en)
|
2012-11-21 |
2017-09-28 |
Janssen Biotech, Inc. |
Bispecific EGFR/C-Met Antibodies
|
|
WO2015043614A1
(en)
|
2013-09-26 |
2015-04-02 |
Biontech Ag |
Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
|
|
CN106456749B
(zh)
|
2014-03-11 |
2021-03-30 |
小利兰·斯坦福大学托管委员会 |
抗SIRPα抗体和双特异性巨噬细胞增强型抗体
|
|
WO2015188777A1
(en)
|
2014-06-12 |
2015-12-17 |
Shanghai Fochon Pharmaceutical Co Ltd |
Certain protein kinase inhibitors
|
|
HUE054848T2
(hu)
|
2014-10-13 |
2021-09-28 |
Yuhan Corp |
Vegyületek és készítmények EGFR mutáns kináz aktivitás módosítására
|
|
EP3221358B1
(en)
|
2014-11-18 |
2021-07-21 |
Janssen Pharmaceutica, N.V. |
Cd47 antibodies, methods, and uses
|
|
CN113150147A
(zh)
*
|
2015-03-16 |
2021-07-23 |
塞尔德克斯医疗公司 |
抗-met抗体及其使用方法
|
|
SMT202100230T1
(it)
|
2015-10-23 |
2021-07-12 |
Fundacio Inst De Recerca Biomedica Irb Barcelona |
Molecole di legame che inibiscono la crescita tumorale
|
|
EP3383435A4
(en)
|
2015-11-30 |
2019-07-10 |
Medimmune, LLC |
OPTIMIZED RATES OF AMINO ACIDS AND SUGARS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS HAVING HIGH CONCENTRATIONS IN PROTEIN-BASED THERAPEUTICS
|
|
US10813933B2
(en)
|
2016-05-17 |
2020-10-27 |
Japanese Foundation For Cancer Research |
Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance
|
|
CN116333130A
(zh)
|
2016-05-24 |
2023-06-27 |
英斯梅德股份有限公司 |
抗体及其制备方法
|
|
GB201611123D0
(en)
|
2016-06-27 |
2016-08-10 |
Euremab Srl |
Anti met antibodiesand uses thereof
|
|
HUE054571T2
(hu)
|
2016-09-14 |
2021-09-28 |
Merck Patent Gmbh |
Hatékony tumorgátlásra szolgáló C-MET elleni ellenanyagok és ellenanyag-drog konjugátumaik
|
|
KR102771603B1
(ko)
|
2016-11-17 |
2025-02-24 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물
|
|
CA3054381A1
(en)
|
2017-02-22 |
2018-08-30 |
University Of Saskatchewan |
Egfr-binding agents and uses thereof
|
|
AR111469A1
(es)
|
2017-04-21 |
2019-07-17 |
Yuhan Corp |
Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
|
|
EP3625713A1
(en)
|
2017-05-19 |
2020-03-25 |
Guardant Health, Inc. |
Methods and systems for detecting insertions and deletions
|
|
WO2019022486A1
(en)
|
2017-07-28 |
2019-01-31 |
Yuhan Corporation |
NOVEL INTERMEDIATES USEFUL FOR SYNTHESIZING AMINOPYRIMIDINE DERIVATIVES, PROCESS FOR PREPARING THE SAME, AND PROCESS FOR PREPARING AMINOPYRIMIDINE DERIVATIVES THEREWITH
|
|
MY201038A
(en)
|
2017-07-28 |
2024-01-31 |
Yuhan Corp |
Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same
|
|
SG11201913517UA
(en)
|
2017-07-28 |
2020-02-27 |
Yuhan Corp |
Improved process for preparing aminopyrimidine derivatives
|
|
WO2020055643A2
(en)
|
2018-09-04 |
2020-03-19 |
Rain Therapeutics Inc. |
Compounds, compositions and methods for treating or preventing her-driven cancers
|
|
KR20200043618A
(ko)
|
2018-10-18 |
2020-04-28 |
주식회사유한양행 |
아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
|
|
BR112021016149A2
(pt)
|
2019-02-26 |
2021-10-13 |
Janssen Biotech, Inc. |
Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met
|
|
MX2021011948A
(es)
|
2019-03-29 |
2022-01-04 |
Univ Texas |
Compuestos con actividad antitumoral contra células cancerígenas que llevan inserciones de exon 20 effr o her2.
|
|
CA3132816A1
(en)
|
2019-04-17 |
2020-10-22 |
Board Of Regents, The University Of Texas System |
Compounds with anti-tumor activity against cancer cells bearing tyrosine kinase inhibitor resistant egfr mutations
|
|
EP3956035A4
(en)
|
2019-04-17 |
2023-01-25 |
Board of Regents, The University of Texas System |
ANTI-CANCER LINKS WITH TYROSINE KINASE RESISTANT EGFR MUTATIONS
|
|
US11850248B2
(en)
|
2019-05-14 |
2023-12-26 |
Yuhan Corporation |
Therapies with 3rd generation EGFR tyrosine kinase inhibitors
|
|
US11879013B2
(en)
|
2019-05-14 |
2024-01-23 |
Janssen Biotech, Inc. |
Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
|
|
JP7783182B2
(ja)
|
2020-02-12 |
2025-12-09 |
ヤンセン バイオテツク，インコーポレーテツド |
ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療
|